Related Experiment Videos

Targeting oncogene expression in a childhood cancer

Matthew C Tuthill¹, Randal K Wada

¹Cancer Research Center of Hawaii, USA.

Hawaii Medical Journal

|November 25, 2003

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.

Genome medicine·2024

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.

International journal of cancer·2023

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

Cancer reports (Hoboken, N.J.)·2022

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.

Cancer research·2021

Leadership, behavioral science, and interprofessional teamwork.

Translational behavioral medicine·2020

See all related articles